Nathan Klopfenstein1,2, James E Cassat2,3,4,5,6, Andrew Monteith2,3, Anderson Miller2,3, Sydney Drury2,3, Eric Skaar2,3, C Henrique Serezani1,2,3. 1. Division of Infectious Disease, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee. 2. Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee. 3. Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center, Nashville, Tennessee. 4. Department of Pediatrics, Division of Pediatric Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee. 5. Vanderbilt Center for Bone Biology, Vanderbilt University Medical Center, Nashville, Tennessee. 6. Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee.
Abstract
Staphylococcus aureus is a Gram-positive bacterium that colonizes almost every organ in humans and mice and is a leading cause of diseases worldwide. S. aureus infections can be challenging to treat due to widespread antibiotic resistance and their ability to cause tissue damage. The primary modes of transmission of S. aureus are via direct contact with a colonized or infected individual or invasive spread from a colonization niche in the same individual. S. aureus can cause a myriad of diseases, including skin and soft tissue infections (SSTIs), osteomyelitis, pneumonia, endocarditis, and sepsis. S. aureus infection is characterized by the formation of purulent lesions known as abscesses, which are rich in live and dead neutrophils, macrophages, and surrounded by a capsule containing fibrin and collagen. Different strains of S. aureus produce varying amounts of toxins that evade and/or elicit immune responses. Therefore, animal models of S. aureus infection provide a unique opportunity to understand the dynamics of organ-specific immune responses and modifications in the pathogen that could favor the establishment of the pathogen. With advances in in vivo imaging of fluorescent transgenic mice, combined with fluorescent/bioluminescent bacteria, we can use mouse models to better understand the immune response to these types of infections. By understanding the host and bacterial dynamics within various organ systems, we can develop therapeutics to eliminate these pathogens. This module describes in vivo mouse models of both local and systemic S. aureus infection.
Staphylococcus aureus is a Gram-positive bacterium that colonizes almost every organ in humans and mice and is a leading cause of diseases worldwide. S. aureus infections can be challenging to treat due to widespread antibiotic resistance and their ability to cause tissue damage. The primary modes of transmission of S. aureus are via direct contact with a colonized or infected individual or invasive spread from a colonization niche in the same individual. S. aureus can cause a myriad of diseases, including skin and soft tissue infections (SSTIs), osteomyelitis, pneumonia, endocarditis, and sepsis. S. aureus infection is characterized by the formation of purulent lesions known as abscesses, which are rich in live and dead neutrophils, macrophages, and surrounded by a capsule containing fibrin and collagen. Different strains of S. aureus produce varying amounts of toxins that evade and/or elicit immune responses. Therefore, animal models of S. aureus infection provide a unique opportunity to understand the dynamics of organ-specific immune responses and modifications in the pathogen that could favor the establishment of the pathogen. With advances in in vivo imaging of fluorescent transgenic mice, combined with fluorescent/bioluminescent bacteria, we can use mouse models to better understand the immune response to these types of infections. By understanding the host and bacterial dynamics within various organ systems, we can develop therapeutics to eliminate these pathogens. This module describes in vivo mouse models of both local and systemic S. aureus infection.
Authors: Andrew S Hendrix; Thomas J Spoonmore; Aimee D Wilde; Nicole E Putnam; Neal D Hammer; Daniel J Snyder; Scott A Guelcher; Eric P Skaar; James E Cassat Journal: Antimicrob Agents Chemother Date: 2016-08-22 Impact factor: 5.191
Authors: Yi Guo; Romela Irene Ramos; John S Cho; Niles P Donegan; Ambrose L Cheung; Lloyd S Miller Journal: Antimicrob Agents Chemother Date: 2012-12-03 Impact factor: 5.191
Authors: Alice G Cheng; Hwan Keun Kim; Monica L Burts; Thomas Krausz; Olaf Schneewind; Dominique M Missiakas Journal: FASEB J Date: 2009-06-12 Impact factor: 5.191
Authors: Nicole E Putnam; Laura E Fulbright; Jacob M Curry; Caleb A Ford; Jenna R Petronglo; Andrew S Hendrix; James E Cassat Journal: PLoS Pathog Date: 2019-04-12 Impact factor: 6.823
Authors: William J Perry; Jeffrey M Spraggins; Jessica R Sheldon; Caroline M Grunenwald; David E Heinrichs; James E Cassat; Eric P Skaar; Richard M Caprioli Journal: Proc Natl Acad Sci U S A Date: 2019-10-14 Impact factor: 11.205
Authors: Andrew J Monteith; Jeanette M Miller; Jonathan M Williams; Kelsey Voss; Jeffrey C Rathmell; Leslie J Crofford; Eric P Skaar Journal: J Immunol Date: 2021-12-20 Impact factor: 5.422
Authors: Andrew J Monteith; Jeanette M Miller; William N Beavers; Lillian J Juttukonda; Eric P Skaar Journal: Infect Immun Date: 2022-01-18 Impact factor: 3.609
Authors: Andrew J Monteith; Jeanette M Miller; William N Beavers; K Nichole Maloney; Erin L Seifert; Gyorgy Hajnoczky; Eric P Skaar Journal: Infect Immun Date: 2021-12-06 Impact factor: 3.609
Authors: Caleb A Ford; Ian M Hurford; Laura E Fulbright; Jacob M Curry; Christopher T Peek; Thomas J Spoonmore; Virginia Cruz Victorio; Joshua R Johnson; Sun H Peck; James E Cassat Journal: Front Cell Infect Microbiol Date: 2022-09-20 Impact factor: 6.073